✦ LIBER ✦

A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

✍ Scribed by Gary H. Lyman; Stephanie J. Green; Peter M. Ravdin; Charles E. Geyer; Christy A. Russell; Stanley P. Balcerzak; G. Thomas Budd; Silvana Martino

Book ID: 111575054
Publisher: Springer US
Year: 2004
Tongue: English
Weight: 130 KB
Volume: 85
Category: Article
ISSN: 0167-6806
DOI: 10.1023/b:brea.0000025405.63953.f9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expanded phase II trial of paclitaxel in

Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study

✍ Charles E. Geyer; Stephanie J. Green; Carol M. Moinpour; Janet O'Sullivan; Donna 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 740 KB

Phase II study of gemcitabine, doxorubic

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience

✍ Alessandro Passardi; Ilaria Massa; Wainer Zoli; Lorenzo Gianni; Carlo Milandri; 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 267 KB

A randomized phase II study of combinati

A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer

✍ Cresta, S. 📂 Article 📅 2004 🏛 Oxford University Press 🌐 English ⚖ 100 KB

A phase II study of paclitaxel plus carb

A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma

✍ Edith A. Perez; David W. Hillman; Philip J. Stella; James E. Krook; Lynn C. Hart 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 3 views

## BACKGROUND. This Phase II multicenter study evaluated the efficacy and toxicity of paclitaxel (200 mg/m 2 by 3-hour infusion) with carboplatin (area under the curve 6 mg/mL per minute) administered every 3 weeks as first-line therapy for women with metastatic breast carcinoma. ## METHODS. Eligi

A Phase II Study of Imatinib Mesylate an

A Phase II Study of Imatinib Mesylate and Capecitabine in Metastatic Breast Cancer: Southwest Oncology Group Study 0338

✍ Helen K. Chew; William E. Barlow; Kathy Albain; Danika Lew; Allen Gown; Daniel F 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 109 KB

Docetaxel and Doxorubicin Compared With

Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial

✍ Nabholtz, J.-M. 📂 Article 📅 2003 🏛 American Society of Clinical Oncology 🌐 English ⚖ 150 KB